Abstract
The vanilloid subfamily of transient receptor potential (TRPV) ion channels serves critical functions in sensory signaling in specialized cells and intact organisms ranging from yeast to primates. As thermosensors, chemosensors, and/or mechanosensors, these channels monitor the local environment and integrate and respond to multiple stimuli distinctively. More than a decade of research on the founding member of the subclass, TRPV1, has led to advancement of multiple antagonists into the clinic for the treatment of chronic pain. In recent years the comprehensive knowledge accessed through these studies has been applied to enhance understanding of other TRPV isoforms and, in particular, to determine whether they, too, represent promising targets for drug discovery. This review focuses on emerging data that define a role for TRPV3 in transducing signals in pain pathways and identify antagonists that demonstrate efficacy in relevant preclinical behavioral models.
Keywords: Antagonist, ion channel, pain, transient receptor potential, TRPV3, thermosensors, chemosensors, mechanosensors, multiple stimuli, multiple antagonists, chronic pain, TRPV isoforms, drug discovery, transducing signals in pain pathways, efficacy
Current Topics in Medicinal Chemistry
Title: Analgesic Potential of TRPV3 Antagonists
Volume: 11 Issue: 17
Author(s): Regina M. Reilly and Philip R. Kym
Affiliation:
Keywords: Antagonist, ion channel, pain, transient receptor potential, TRPV3, thermosensors, chemosensors, mechanosensors, multiple stimuli, multiple antagonists, chronic pain, TRPV isoforms, drug discovery, transducing signals in pain pathways, efficacy
Abstract: The vanilloid subfamily of transient receptor potential (TRPV) ion channels serves critical functions in sensory signaling in specialized cells and intact organisms ranging from yeast to primates. As thermosensors, chemosensors, and/or mechanosensors, these channels monitor the local environment and integrate and respond to multiple stimuli distinctively. More than a decade of research on the founding member of the subclass, TRPV1, has led to advancement of multiple antagonists into the clinic for the treatment of chronic pain. In recent years the comprehensive knowledge accessed through these studies has been applied to enhance understanding of other TRPV isoforms and, in particular, to determine whether they, too, represent promising targets for drug discovery. This review focuses on emerging data that define a role for TRPV3 in transducing signals in pain pathways and identify antagonists that demonstrate efficacy in relevant preclinical behavioral models.
Export Options
About this article
Cite this article as:
M. Reilly Regina and R. Kym Philip, Analgesic Potential of TRPV3 Antagonists, Current Topics in Medicinal Chemistry 2011; 11 (17) . https://dx.doi.org/10.2174/156802611796904889
DOI https://dx.doi.org/10.2174/156802611796904889 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amiodarone-Induced SIADH: Two Cases Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Neurotrophin Receptor-Based Strategies for Alzheimers Disease
Current Alzheimer Research Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets Synthesis of a Novel Class of gem-Phosphonate-Phosphates by Reductive Cleavage of the Isoxazolidine Ring
Current Organic Synthesis Association between Proliferative Diabetic Retinopathy and Serum Bile Acid Level in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Tuberculosis, an Old Disease Lacking New Therapeutic Drugs
Current Drug Therapy Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effect of Adding Proprioceptive Exercise to Balance Training in Older Adults with Diabetes: A Systematic Review
Current Diabetes Reviews Editorial [Hot Topic: Antiangiogenesis in Chronic Inflammation (Guest Editor: Domenico Ribatti)]
Current Drug Targets - Inflammation & Allergy